Prospective, non-interventional study on the real-world use of certoparin in daily practice--the PROMEMBER study.

Background: We aimed to verify safety and effectiveness of certoparin real-world use and to identify predictors of thromboembolic events or bleeding.

Methods: This was a non-interventional study documenting patients at hospital- or office-based physicians.

Results: Patients' (n = 1407) mean age was 53.

Bridging with the Low molecular weight heparin certoparin in patients requiring temporary discontinuation of oral anticoagulation - the non-interventional, retrospective REMEMBER study.

Background: Bridging of a temporal discontinuation of oral anticoagulation with low molecular weight heparins (LMWH) is common practice. Specific data on the LMWH certoparin are however limited despite its wide spread use. We aimed to assess effectiveness and safety of certoparin in this indication under real world conditions.

Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients.

The peri- and postsurgical thromboembolic prophylaxis with low molecular weight heparins is a well established therapy regimen, but the optimum duration of prophylaxis after surgery still remains uncertain. A few studies have pointed to the fact that the thromboembolic risk of high-risk patients persists longer than the in-hospital period correlating with respective hypercoagulatory conditions. The aim of the present study was to test if a prolongation of thromboprophylaxis with the low molecular weight heparin Certoparin further reduces the rate of thromboembolism in high-risk patients after orthopedic surgery.